Nocturne Acquisition Corporation intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the disruptive technology market. The company was incorporated in 2020 and is based in La Jolla, California.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
SANTA ANA, CA / ACCESSWIRE / January 30, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that the Board of Directors has voted in favor of postponing the meeting date for the Extraordinary General Meeting that was to be held on January 30, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. The Extraordinary General Meeting will now be held virtually on February 6, 2024 at 10:00 a.m. Eastern Time, and the Company plans to continue to solicit proxies from shareholders during the period prior to the Extraordinary General Meeting. The record date for the Extraordinary General Meeting remains the close of business on
WILMINGTON, Del. and INGLEWOOD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Nocturne Acquisition Corporation (NASDAQ:MBTC, MBTCU, MBTCR))) ("Nocturne") and Cognos Therapeutics, Inc. ("Cognos") today announced the engagement of Chardan, a leading global investment bank, in the role of capital markets advisor to Nocturne in the highly anticipated business combination transaction (the "Business Combination") with Cognos. This strategic move marks Cognos's journey towards becoming a publicly traded company on the NASDAQ Stock Exchange. Chardan, a distinguished independent, full-service investment bank, boasts two decades of experience in addressing the diverse capital market requirements of bo
Transaction Expected to Accelerate the Research and Advancement of Cognos' Proprietary and Innovative Implantable Drug Delivery Pump to Improve Outcomes for Treatment of Brain Cancers and Other Neurological DiseasesWILMINGTON, DE / ACCESSWIRE / August 16, 2023 / Nocturne Acquisition Corporation (NASDAQ:MBTC)(NASDAQ:MBTCU)(NASDAQ:MBTCR) (the "Company", "MBTC" or "Nocturne"), today announced the submission via Edgar, the U.S. Securities and Exchange Commission's ("SEC") online portal, for filing of a registration statement on Form S-4 (the "Registration Statement") with the SEC, which includes a preliminary proxy statement/prospectus in connection with the proposed business combination (the "B
WILMINGTON, DE / ACCESSWIRE / May 30, 2023 / Nocturne Acquisition Corporation (NASDAQ:MBTC, MBTCU, MBTCR))) (the "Company", "MBTC"), today announced that it has received a second notification (the "Second Notification") on May 24, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the "Form 10-Q"), and remaining delinquent in filing its Annual Report on Form 10-K for the period ended December 31, 2022 (the "Form 10-K"). The Second Notification advised the Company that it was not in compliance with Nasdaq's continued listing requirements under the timely
Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke.Cognos' lead product candidate is the SINNAISTM Implantable Smart Pump, believed to be the world's first implantable device under development for the metronomic delivery of therapeutics for neurological diseases, including brain cancer.Transaction expected to provide Cognos with enhanced access to capital markets, enabling it to accelerate the research and advancement of its proprietary and innovativ
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
SC 13G/A - Nocturne Acquisition Corp (0001837344) (Subject)
Shares of Peraso Inc. (NASDAQ:PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Peraso posted a quarterly loss of $8.52 per share, versus analysts’ estimates for a loss of $3.76 per share. The company’s quarterly sales came in at $1.83 million versus expectations of $1.70 million. Peraso shares tumbled 23.3% to $1.32 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Ontrak, Inc. (NASDAQ:OTRK) shares climbed 197.8% to $0.5660 ahead of the company's presentation at the 36th Annual Roth Conference. Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) gained 97.3% to $20.99 after the company anno
- SEC Filing
Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke. Cognos' lead product candidate is the SINNAISTM Implantable Smart Pump, believed to be the world's first implantable device under development for the metronomic delivery of therapeutics for neurological diseases, including brain cancer. Transaction expected to provide Cognos with enhanced access to capital markets, enabling it to accelerate the research and advancement of its proprietary and inn
15-12G - Nocturne Acquisition Corp (0001837344) (Filer)
25-NSE - Nocturne Acquisition Corp (0001837344) (Subject)
8-K - Nocturne Acquisition Corp (0001837344) (Filer)
NT 10-K - Nocturne Acquisition Corp (0001837344) (Filer)
425 - Nocturne Acquisition Corp (0001837344) (Subject)
8-K - Nocturne Acquisition Corp (0001837344) (Filer)
425 - Nocturne Acquisition Corp (0001837344) (Subject)
8-K - Nocturne Acquisition Corp (0001837344) (Filer)
425 - Nocturne Acquisition Corp (0001837344) (Subject)
425 - Nocturne Acquisition Corp (0001837344) (Subject)
3 - Nocturne Acquisition Corp (0001837344) (Issuer)
3 - Nocturne Acquisition Corp (0001837344) (Issuer)
3 - Nocturne Acquisition Corp (0001837344) (Issuer)
3 - Nocturne Acquisition Corp (0001837344) (Issuer)
3 - Nocturne Acquisition Corp (0001837344) (Issuer)